anti-Golimumab ELISA Kit (Simponi®) (ab237662)
Key features and details
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (qualitative)
- Reacts with: Human
Overview
-
Product name
anti-Golimumab ELISA Kit (Simponi®)
See all Golimumab kits -
Detection method
Colorimetric -
Sample type
Serum, Plasma -
Assay type
Sandwich (qualitative) -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
anti-Golimumab ELISA Kit (Simponi®) (ab237662) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Golimumab in biological matrices such as human serum and plasma.
Golimumab (Simponi®) is a human immunoglobulin G1κ monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-α (TNFα). Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Micro ELISA Plate 1 unit Positive Control 1 x 0.25ml Negative Control 1 x 0.5ml Assay Buffer 1 x 12ml Peroxidase Conjugate 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 1 unit -
Relevance
Golimumab (Simponi®) is a human immunoglobulin G1? monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-a (TNFa). In 2009, it was approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adult patients. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF. -
Alternative names
- Simponi
- tumor necrosis factor-a